PepGen Inc. announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Both individuals are recognized industry veterans, bringing decades of executive experience in the life sciences sector to the company.
Ms. Wyman's expertise includes scaling manufacturing for mid- to late-stage clinical trials and navigating global regulatory agencies, having played a pivotal role in transforming Acceleron Pharma Inc. to a commercial-stage firm. Dr. Finer brings extensive experience in driving scientific innovation and translating breakthrough research into therapies, with a background in genetic therapies and leadership roles at multiple biotech companies.
These appointments are expected to broaden and strengthen PepGen's Board of Directors at a crucial time for the company. Their guidance will be valuable as PepGen advances its mid-stage clinical trials and works to unlock the full potential of its Enhanced Delivery Oligonucleotide platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.